What Has Been the Progress and Growth of the Blood Plasma Derivatives Market in Recent Years?
The blood plasma derivatives market has seen considerable growth due to a variety of factors.
•In recent times, the market size of blood plasma derivatives has seen considerable growth. The market is predicted to expand from $51.81 billion in 2024 to $56.24 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.6%.
Factors that contributed to the historical growth include a rise in the incidence of hemophilia and bleeding disorders, an increase in the aged population, heightened awareness and diagnosis, a surge in surgical procedures, and the global blood transfusion services.
What Can Be Expected from the Blood Plasma Derivatives Market in the Coming Years?
The blood plasma derivatives market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the blood plasma derivatives market is projected to witness significant expansion. The market is expected to reach $80.42 billion in 2029, with a compound annual growth rate (CAGR) of 9.4%.
This anticipated growth during the forecast period is due to the emergence of therapies for rare diseases, increase in chronic diseases, a rise in healthcare expenditure, focus on patient-oriented treatment methods, and the expansion of healthcare infrastructure. Key trends for the forecast period comprise improvements in fractionation technologies, patient-focused approaches, collaborations and partnerships, widening usage in neurology, and innovative advancements in plasma fractionation.
What Are the Critical Driver Fuelling the Blood Plasma Derivatives Market's Growth?
The rise in cases of immunodeficiency disorders is anticipated to fuel the expansion of the blood plasma derivatives market. Immunodeficiency disorders, either complete or partial, compromise the immune system. Blood plasma derivatives are utilized in the treatment of numerous medical conditions, immune deficiency disorders being one of them. Plasma, a mixture of proteins and salts, houses over 100 different proteins. Of these, immunoglobulins are especially significant for managing primary immunodeficiencies. Deficiencies in macro and micronutrients caused by poor or insufficient nutrition can result in immunodeficiency. For example, in March 2022, as reported by the Allergy, Asthma & Clinical Immunology, the most prevalent condition was Common Variable Immunodeficiency (CVID), with 16.6% of individuals in the US, 12.9% internationally, and 13.9% globally being affected. Consequently, the escalating instances of immune deficiency disorders are propelling the expansion of the blood plasma derivatives market.
How Is the Blood Plasma Derivatives Market segmented?
The blood plasma derivatives market covered in this report is segmented –
1) By Type: Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Other Types
2) By Application: Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, Von Willebrand's Disease, Other Applications
3) By End-User: Hospitals, Clinics, Other End-Users
Subsegments:
1) By Albumin: Human Serum Albumin, Recombinant Albumin
2) By Factor VIII: Plasma-Derived Factor VIII, Recombinant Factor VIII
3) By Factor IX: Plasma-Derived Factor IX, Recombinant Factor IX
4) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)
5) By Hyperimmune Globulin: Specific Pathogen-Reduced Hyperimmune Globulin, Standard Hyperimmune Globulin
6) By Other Types: Fibrinogen, Clotting Factor Concentrates, Plasma-Derived Proteins
Pre-Book The Blood Plasma Derivatives Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing the Blood Plasma Derivatives Market?
Leading businesses in the blood plasma derivatives market are honing in on strategic alliances to bolster their market standing. This cooperation ensures that patients requiring these essential plasma-derived drugs have a reliable and consistent source, which will address the escalating demand for immunoglobulins in France and other parts of the world. Take for example, in January 2022, Kedrion S.p.A. a biopharmaceutical firm in Italy known for creating, manufacturing, and distributing plasma-derived treatments teamed up with LPB, a pharmaceutical company from the UK that excels in biological medicinal products. Kedrion is planning to use LFB plasma from France procured by the Etablissement Français du Sang (EFS) to manufacture immunoglobulins in Hungary. In compliance and under the watch of the French health authorities, the present supply of this vital protein will be increased using these imports from LFB in France, with the intention of distributing it to hospitals nationwide.
Who Are the Key Players in the Blood Plasma Derivatives Market?
Major companies operating in the blood plasma derivatives market include:
• Bayer AG
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Baxter International Inc.
• CSL Limited
• Meiji Group
• Grifols S.A.
• Shire Pharmaceuticals Inc.
• GC Biopharma Corp
• Emergent BioSolutions Inc.
• Shanghai Raas Blood Products Co Ltd.
• Kedrion S.p.A.
• Sanquin
• Biotest AG
• Bio Products Ltd.
• ADMA Biologics Inc.
• China Biologic Products Holdings Inc.
• BioIVT
• PlasmaGen BioSciences Pvt. Ltd.
• Virchow Biotech Private Limited
• LFB S.A.
• Intas Pharmaceuticals Ltd.
• Octapharma Plasma
What Is The Most Dominant Region In The Blood Plasma Derivatives Market?
North America was the largest region in the blood plasma derivatives market in 2024. The regions covered in the blood plasma derivatives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
